Dendrotoxin K is a Kv1.1 channel blocker. Dendrotoxin K determines glutamate release in CA3 neurons in a time-dependent manner through the control of the presynaptic spike waveform.

PBFI-AM is a useful tool to determine intracellular K+ content.

Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes.

N-Bromoacetamide can irreversibly remove sodium channel inactivation in the cytoplasmic face of the membrane, also decreasing K current rapid inactivation.

NS-8, a pyrrole derivative, activates the Ca2+-sensitive k+-channel. NS-8 can suppress the micturition reflex by decreasing afferent pelvic nerve activity. NS-8 can be used in the research of urinary frequency and incontinence.

Clobutinol is a compound that has anti-tussive effects. Clobutinol affects heart rate and blood pressure, it can be used for cough related research.

TRAM-39 is a selective blocker of intermediate conductance Ca2+-activated K+ (IKCa) channels. TRAM-39 inhibits KCa3.1 channel with an IC50 value of 60 nM. TRAM-39 can be used for the research of ataxia, epilepsy, memory disorders, schizophrenia and Parkinson’s disease.

β-Bag cell peptide is a neuroactive peptide. β-Bag cell peptide elevates cyclic AMP levels in the bag cell neurons. β-Bag cell peptide decreases the amplitudes of the voltage-dependent potassium currents.

Foslevcromakalim (QLS-101) is a ATP-sensitive potassium channel opener. Foslevcromakalim is the prodrug used for ocular hypotensive effect.

Etidocaine (hydrochloride) is a long aminoamide local anaesthetic that inhibits flicker potassium channel with an IC50 of 8.6 µM.

ML213 is a novel potent, selective KCNQ2 (Kv7.2) and KCNQ4 (Kv7.4) activator with EC50 of 230 and 510 nM, respectively. ML213 displays >80-fold selectivity over other related potassium channels (KCNQ1/3/5). ML213 causes significant hyperpolarization in mesenteric artery smooth muscle cells, shows potent vasorelaxant effects in different blood vessels.

3hi2one-G4 is a highly selective small molecule activator targeting GIRK4 homomeric channels, does not activate GIRK2, GIRK1/2 or GIRK1/4 channels.

ACOU001 (ACOU 001) is a potent small-molecule agonist of Kv7.4 (KCNQ4) channel with potential effect against ge-related hearing loss (ARHL) and other hearing impairments related to compromised KV7.4 function.

ACOU085 (ACOU 085) is a potent small-molecule agonist of Kv7.4 (KCNQ4) channel with higher potency than ML-213 in the nanomolar range.

AUT00201 is a potent, selective Kv3 potassium channel modulator with potential for the treatment of rare epilepsy syndromes.

BK channel modulator BC5 is an allosteric modulator of BK type Ca2+-activated K+ channels, interacts with the CTD-VSD interface and specifically modulates the Ca2+ dependent activation mechanism.

C101248 is the first selective small-molecule inhibitor of tandem pore domain halothane-inhibited K+ channel 1 (THIK-1) with IC50 of 50 nM for both mouse and human THIK-1.

KCNQ2 activator Ebio1 is a potent and subtype-selective activator for the voltage-gated potassium channel KCNQ2 (Kv7.2) with EC50 of 247.3 nM, directly opens the KCNQ2 channel.

LAKI (Light Activated K+ channel Inhibitor) is a specific photoswitchable inhibitor of the pain-related two-pore-domain potassium (K2P) TREK and TRESK channels.

ML308 (ML 308) is a potent, selective inhibitor of two-pore domain potassium channel KCNK9 (TASK-3, K2P9.1) with IC50 of 130 nM in thallium influx fluorescent assays and 413 nM in automated electrophysiology assays, respectively.

NIP-142 (NIP142) is an anti-arrhythmic agent by targeting cardiac K+ channel Kv1.5 (Kv1.5) currents, inhibits the steady-state phase with IC50 of 4.75 uM.

NPBA is a potent, selective pharmacological activator for K2P channel TASK-3 with EC50 of 6.7 uM (TASK-3 whole-cell currents), shows good selectivity between TASK channels.